References
- Jones A. L., Cunningham D. The clinical care of patients receiving chemotherapy. In Emesis in anti-cancer therapy. Mechanisms and treatment, P. L.R. Andrews, G. J. Sanger. Chapman and Hall Medical, London 1993; 229–246
- Jantunen I. T., Muhonen T. T., Kataja V. V., Flander M. K., Teerenhovi L. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy. A randomized study. Eur J Cancer 1993; 29A: 1669–1672
- Altmaier E. M., Ross W. E., Moore K. A pilot investigation of the psychologic function of patients with anticipatory vomiting. Cancer 1982; 49: 201–204
- Cella D. F., Pratt A., Holland J. C. Persistent anticipatory nausea, vomiting and anxiety in cured Hodgkin's disease patients after completion of chemotherapy. Am. J. Psychiatry 1986; 143: 641–643
- Nerenz D. R., Leventhal H., Easterling D. V., Love R. R. Anxiety and drug taste as predictors of anticipatory nausea in cancer chemotherapy. J. Clin. Oncol. 1986; 4: 224–233
- Andrykowski M. A. The role of anxiety in the development of anticipatory nausea in cancer chemotherapy: a review and synthesis. Psychosom. Med. 1990; 52: 458–475
- Greenberg D. B., Suxman O. S., Clarke J. Alpra-zolam for phobic nausea and vomiting related to cancer chemotherapy. Cancer Treat. Rep. 1987; 71: 549–550
- Holland J. C., Morrow G. R., Schmale A. A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. J. Clin. Oncol. 1991; 9: 1004–1011
- Razavi D., Delvaux N., Farvacques C., De Brier F., Van Heer C., Kaufman L. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double blind, placebo-controlled study assessing the usefulness of alprazolam. J. Clin. Oncol. 1993; 11: 1384–1390
- Andrews P. L.R., Davis C. J. The mechanism of eme-sis induced by anti-cancer therapies. In Emesis in anti-cancer therapy. Mechanisms and treatment, P. L.R. Andrews, G. J. Sanger. Chapman and Hall Medical, London 1993; 113–161
- Andrews P. L.R., Bhandari P., Davey P. T. Are all 5-HT3 receptor antagonists the same ?. Eur. J. Cancer 1992; 28A(suppl. 1)S2–S6
- Upward J. W., Arnold B. D.C., Link C., Pierce D. M., Allen A., Tasker T. C. The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist. Eur, J. Cancer 1990; 26(Suppl. 1)S12–S15
- Kaye S. B., Khayat D., Aapro M., Diehl V. Who should receive a 5-HT3 antagonist ?. Lancet 1992; 340: 1107–1108
- Lazlo J., Clark R. A., Hanson D. C. Lorazepam in cancer patients treated with cisplatin: a drug with antiemetic, amnesic and anxiolytic effects. J. Clin. Oncol. 1985; 3: 864–869
- Tonato M., Roila F., Del Favero A. Methodology of antiemetic trials: a review. Ann. Oncol. 1991; 2: 107–114
- Blijham G. H. Does granisetron remain effective over multiple cycles ?. Eur J. Cancer 1992; 28A(Suppl.l)S17–S21, for the Granisetron study group.(
- Zook D. J., Yasko J. M. Psychologic factors: Their effect on nausea and vomiting experienced by clients receiving chemotherapy. Oncol. Nurs. Forum 1983; 10: 76–81
- The Italian Group for Antiemetic Research. Dexametha-sone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N. Engl. J. 1995; 332: 1–5, Med.